GOVX

GeoVax Labs, Inc. (GOVX) | Rumor.io

GeoVax Labs

GOVX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,746

Bullish sentiment (50-day avg)71%

Price to earnings ratio-0.02

Market capitalization3.1M

Earnings per share-5.62

Dividend yield (TTM)—

Revenue (annual)2.5M

Net income (annual)-21.5M

Social

What share of all stock conversation is about GOVX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Aug 27

$GOVX is trading at $2, a key level for the stock.
The author is watching for a change in volume and momentum to determine the stock's future direction.
The author believes that a momentum shift could significantly impact $GOVX's price and sentiment.

Generated by AI

Sentiment

Of the messages about GOVX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -73.91	89.81% +10.23
Bearish	—	—	100% +73.91	10.19% -10.23

Bullish· May 26

$GOVX has shown a strong short-term breakout, with a 32% increase in a single day, indicating a bullish trend.
The stock's current price of $3.64 with a pre-market high of $3.79 suggests potential for further growth, making it a good candidate for holding for higher returns.
With a personal target of $5.52 and a belief that the stock will continue to rise, investors are optimistic about the company's future performance.

Bearish· May 26

$GOVX's inability to bring a COVID vaccine to market on time raises concerns about its ability to succeed in the future.
The company's frequent dilution of shareholders' interests when the stock price rises is a significant red flag for investors.
The recent worsening of the Ebola situation and the success of a competing company, CODX, which has seen a 26% increase in stock price, further exacerbates the bearish outlook for $GOVX.

Generated by AI

Topics

Of the messages about GOVX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	82.35%	73.77%
Technical Analysis	—	—	5.88%	14.3%
Macro	—	—	11.76%	5.45%
Analysts	—	—	0%	0.15%
Controversies	—	—	0%	6.04%
Earnings	—	—	0%	0.29%

Announcements· May 26

GeoVax Labs has filed an S-1 registration statement with the SEC, potentially leading to a strong share dilution threat for existing shareholders.
The company is prioritizing resources towards the advancement of its lead programs, GEO-MVA and Gedeptin, while discontinuing active development of GEO-CM04S1.
GeoVax has stopped its COVID-19 vaccine program to focus on mpox/smallpox and cancer drugs, aiming for faster approvals and growth, with its MVA-based vaccine candidate targeting mpox and smallpox advancing under an expedited regulatory pathway.

Controversies· Aug 4

GeoVax Labs' vaccine candidate against ebolavirus showed 100% protection with single immunization in preclinical data published in NPJ Vaccines.
The US has declared a public health emergency to access funds for monkeypox, with cases on the rise across the US, sparking criticism over the administration's handling of the outbreak.
Over 500 confirmed monkeypox cases have been reported in Florida, with some calling for easier access to the drug TPOXX, amid controversy over the government's response to the outbreak.

Technical Analysis· May 22

$GOVX is showing signs of strength, with higher lows building over VWAP, and holding the $2.50 area strong.
The stock is forming a possible flat top breakout, with a clean breakout from intraday consolidation and buyers defending dips aggressively.
A cup-and-handle formation is visible on the 15min chart, with the structure tightening while momentum continues improving underneath.

Generated by AI

Community

Of the messages about GOVX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	85.71%	88.89%	91.67%	47.55%
Newcomers	14.29%	11.11%	8.33%	52.45%

Regulars· May 22

A possible flat top breakout is forming, and a break above $4.10 is needed for further continuation.
A squeeze into $4.5 is expected, with a clearout of the HOD; however, it's unclear if this will happen today or next week.
$GOVX is on an uptrend, with a clean breakout from intraday consolidation, and buyers are defending dips aggressively.

Newcomers· Aug 27

$GOVX has seen a 16.8% increase today, with a relative volume of 12.3x and $3M in trading activity, according to The Watchtower's research.
$GOVX has traded 834K shares, up 5.5% to $0.665, with 2% of the shares available to trade sold short.
$GOVX has seen a sharp increase in trading activity, with technicals climbing and some users entering positions at $0.70 cents.

Generated by AI

Study Shows Protection Against Highly Pathogenic Clade I Mpox Virus and Durable CD8+ T-Cell Responses Findings Support GeoVax's Broader Strategy to Expand the Utility of the MVA Vaccine Platform ATLANTA, GA - September 21, 2026 (NEWMEDIAWIRE) - GeoVa...

8d agoYahoo Finance

12 Health Care Stocks Moving In Friday's After-Market Session

11d agoBenzinga

GeoVax Confirms Bundibugyo Ebola Vaccine Construct

BDBV-Specific Construct Developed Using GeoVax Proprietary Rapid Cloning Technology and Builds on Established Filovirus Vaccine Experience GEO-MVA (Mpox/Smallpox Vaccine) Targeted for Phase 3 Initiation Remains Company Priority ATLANTA, GA - Septembe...

13d agoYahoo Finance

GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial

Independent Evaluation Supports GEO-MVA Pivotal Phase 3 Program Advances GeoVax's Strategy to Expand and Diversify MVA Vaccine Supply ATLANTA, GA - September 14, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology c...

15d agoca.finance.yahoo.com

GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities

ATLANTA, GA - September 10, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high-consequence infectious diseases and solid tumor cancers, today provided an...

19d agoYahoo! Finance Canada

Also Discussed

Investors talking about GOVX also mention

#	Name	Attention
1	SIGA Technologies Inc.SIGA	0%new
2	Virax Biolabs Group Ltd.VRAX	0%+0
3	United Maritime CorporationUSEA	0%0
4	Comera Life Sciences Holdings Inc.CMRA	0%0
5	MGAM - Mobile Global Esports Inc.	——
6	Aethlon Medical, Inc.AEMD	0%new
7	Magic Empire Global Ltd Class A Ordinary SharesMEGL	0%0
8	Intelligent Living Application Group Inc.ILAG	0%new
9	TD Ameritrade Holding CorpAMTD	0%0
10	CMRX - Chimerix, Inc.	——

GeoVax Labs, Inc.

Healthcare
Biotechnology

GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on developing vaccines and immunotherapies for infectious diseases and solid tumor cancers. GeoVax’s current portfolio centers on human vaccine candidates that address serious viral threats, including COVID-19, mpox, smallpox, and other high-consequence infectious diseases, alongside oncology programs aimed at difficult-to-treat solid tumors. The company’s pipeline includes vaccine and therapy development built on proprietary platform technologies designed to support immune responses across preventive and therapeutic settings. Its work spans infectious disease prevention, biodefense-related vaccines, and cancer immunotherapy, making GeoVax Labs a specialized player in the biotechnology market with an emphasis on unmet medical needs.

Website

Location

1955 Lake Park Drive

Smyrna, GA, 30080

United States

Social

What share of all stock conversation is about GOVX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% +0	0% 0	0% 0

Aug 27

$GOVX is trading at $2, a key level for the stock.
The author is watching for a change in volume and momentum to determine the stock's future direction.
The author believes that a momentum shift could significantly impact $GOVX's price and sentiment.

Generated by AI

Sentiment

Of the messages about GOVX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -73.91	89.81% +10.23
Bearish	—	—	100% +73.91	10.19% -10.23

Bullish· May 26

$GOVX has shown a strong short-term breakout, with a 32% increase in a single day, indicating a bullish trend.
The stock's current price of $3.64 with a pre-market high of $3.79 suggests potential for further growth, making it a good candidate for holding for higher returns.
With a personal target of $5.52 and a belief that the stock will continue to rise, investors are optimistic about the company's future performance.

Bearish· May 26

$GOVX's inability to bring a COVID vaccine to market on time raises concerns about its ability to succeed in the future.
The company's frequent dilution of shareholders' interests when the stock price rises is a significant red flag for investors.
The recent worsening of the Ebola situation and the success of a competing company, CODX, which has seen a 26% increase in stock price, further exacerbates the bearish outlook for $GOVX.

Generated by AI

Topics

Of the messages about GOVX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	82.35%	73.77%
Technical Analysis	—	—	5.88%	14.3%
Macro	—	—	11.76%	5.45%
Analysts	—	—	0%	0.15%
Controversies	—	—	0%	6.04%
Earnings	—	—	0%	0.29%

Announcements· May 26

GeoVax Labs has filed an S-1 registration statement with the SEC, potentially leading to a strong share dilution threat for existing shareholders.
The company is prioritizing resources towards the advancement of its lead programs, GEO-MVA and Gedeptin, while discontinuing active development of GEO-CM04S1.
GeoVax has stopped its COVID-19 vaccine program to focus on mpox/smallpox and cancer drugs, aiming for faster approvals and growth, with its MVA-based vaccine candidate targeting mpox and smallpox advancing under an expedited regulatory pathway.

Controversies· Aug 4

GeoVax Labs' vaccine candidate against ebolavirus showed 100% protection with single immunization in preclinical data published in NPJ Vaccines.
The US has declared a public health emergency to access funds for monkeypox, with cases on the rise across the US, sparking criticism over the administration's handling of the outbreak.
Over 500 confirmed monkeypox cases have been reported in Florida, with some calling for easier access to the drug TPOXX, amid controversy over the government's response to the outbreak.

Technical Analysis· May 22

$GOVX is showing signs of strength, with higher lows building over VWAP, and holding the $2.50 area strong.
The stock is forming a possible flat top breakout, with a clean breakout from intraday consolidation and buyers defending dips aggressively.
A cup-and-handle formation is visible on the 15min chart, with the structure tightening while momentum continues improving underneath.

Generated by AI

Community

Of the messages about GOVX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	85.71%	88.89%	91.67%	47.55%
Newcomers	14.29%	11.11%	8.33%	52.45%

Regulars· May 22

A possible flat top breakout is forming, and a break above $4.10 is needed for further continuation.
A squeeze into $4.5 is expected, with a clearout of the HOD; however, it's unclear if this will happen today or next week.
$GOVX is on an uptrend, with a clean breakout from intraday consolidation, and buyers are defending dips aggressively.

Newcomers· Aug 27

$GOVX has seen a 16.8% increase today, with a relative volume of 12.3x and $3M in trading activity, according to The Watchtower's research.
$GOVX has traded 834K shares, up 5.5% to $0.665, with 2% of the shares available to trade sold short.
$GOVX has seen a sharp increase in trading activity, with technicals climbing and some users entering positions at $0.70 cents.

Generated by AI

GeoVax Labs

Social

Aug 27

Bullish· May 26

Bearish· May 26

Announcements· May 26

Controversies· Aug 4

Technical Analysis· May 22

Regulars· May 22

Newcomers· Aug 27

GeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United States

GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models

12 Health Care Stocks Moving In Friday's After-Market Session

GeoVax Confirms Bundibugyo Ebola Vaccine Construct

GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial

GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities

Also Discussed

GeoVax Labs, Inc.

Company Information

Location

GeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United States

GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models

12 Health Care Stocks Moving In Friday's After-Market Session

GeoVax Confirms Bundibugyo Ebola Vaccine Construct

GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial

GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities

Also Discussed

Social

Aug 27

Bullish· May 26

Bearish· May 26

Announcements· May 26

Controversies· Aug 4

Technical Analysis· May 22

Regulars· May 22

Newcomers· Aug 27